CHA has submitted comments to the Center for Medicare & Medicaid Innovation in response to its anticipated Accelerating Clinical Evidence (ACE) model.
The ACE model would adjust Medicare Part B payment amounts for accelerated approval program drugs to give manufacturers an incentive to expedite and complete confirmatory clinical trials. CMS did not include a timeline for when the model will begin.